[ad_1]
The right cell of the image could not divide due to the absence of CDK12 protein
Researchers at the Salk Institute in America, in a study published in Genes & Development on April 1, described the role of a protein called CDK12 in the non-response of ovarian and prostate cancers to chemotherapy.
Three to five percent of these cancers do not contain this protein, and recent studies have shown that this subgroup responds only to the drugs of immunotherapy and chemotherapy, while the majority of the protein does not respond to the treatment.
"This indicates that for the majority of these cancers, devoid of this protein, chemical inhibitors can be used to facilitate cancer treatment through chemotherapy drugs or even more," said Catherine Jones, lead author of the drug. study, in a report published by the Salik Institute. Sensitivity to immune system therapies as well. "
He adds that protein cell inhibition can not effectively repair DNA and is more likely to die in response to chemotherapy.
Scientists are currently studying how to inhibit this protein in normal cells, which could suggest a new way to prevent its activity in cancer cells and thus introduce a new method of treatment.
Source link
